Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

By A. Wang-Gillam, Chung-Pin Li, G. Bodoky, A. Dean, Y. Shan, G. Jameson, T. Macarulla, Kyung-Hun Lee, D. Cunningham, J. Blanc and 11 more. The Lancet, 2016

980 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/b14d394483c3e9c291d1b4b76eb7201b612a9210

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Wahid Khan
2. C. Ferrone
3. Sindhu Doppalapudi
4. Nagavendra Kommineni
5. Upendra Bulbake

In Oncology

1. W. Hawkins
2. Japanese Gastric Cancer Association

Citations in the corpus

• Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “5 months for those who consumed either fluorouracil or leucovorin [45].”
• Cancer nanomedicine: a review of recent success in drug delivery (2017, methodology): “survival with nanoliposomal irinotecan monotherapy versus fluorouracil and folinic acid (Reproduced with permission from [77])”
• Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, methodology): “Grade 3 or 4 adverse events that occurred most frequently with this regimen were neutropenia (27%), fatigue (14%), diarrhea (13%), and vomiting (11%).(205) Irinotecan liposomal injection, combined with 5-FU/leucovorin, was later approved by the FDA to be used as a subsequent treatment option after g”